The development of therapies that are capable of safely achieving sizeable and sustained body weight loss has proved tremendously challenging. Here, Müller et al. provide an overview of the history of anti-obesity drug development, focusing on lessons learned, ongoing challenges and recent advances in the field.
In this episode, I talk to world-renowned biologist David Sinclair about aging and longevity. David rejects the notion that the deterioration of health is a natural part of growing old and asserts that aging is a disease itself that we need to reverse. But how will a reset of our biological clocks affect our interactions, responses to adversity, morality, and how we live our lives? We discuss the ethical implications of limitless lifespans and also touch on the topics of death, evolution, genetics, medicine, and data tracking.
Bio.
Dr. David Sinclair is a professor in the department of genetics and co-director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School and co-founder of the scientific journal Aging. He is best known for his work on understanding why we age and how to slow its effects. In addition to being a co-founder of several biotechnology companies, he’s the author of the book Lifespan: Why We Age – and Why We Don’t Have To. Dr. Sinclair was listed by TIME magazine as one of the “100 most influential people in the world”.
Continue reading “David Sinclair || Why We Age and Why We Don’t Have To” »
A silicon device that can change skin tissue into blood vessels and nerve cells has advanced from prototype to standardized fabrication, meaning it can now be made in a consistent, reproducible way. As reported in Nature Protocols, this work, developed by researchers at the Indiana University School of Medicine, takes the device one step closer to potential use as a treatment for people with a variety of health concerns.
The technology, called tissue nanotransfection, is a non-invasive nanochip device that can reprogram tissue function by applying a harmless electric spark to deliver specific genes in a fraction of a second. In laboratory studies, the device successfully converted skin tissue into blood vessels to repair a badly injured leg. The technology is currently being used to reprogram tissue for different kinds of therapies, such as repairing brain damage caused by stroke or preventing and reversing nerve damage caused by diabetes.
Bongard said they found that the xenobots, which were initially sphere-shaped and made from around 3,000 cells, could replicate. But it happened rarely and only in specific circumstances. The xenobots used “kinetic replication” — a process that is known to occur at the molecular level but has never been observed before at the scale of whole cells or organisms, Bongard said.
The US scientists who created the first living robots say the life forms, known as xenobots, can now reproduce — and in a way not seen in plants and animals.
Formed from the stem cells of the African clawed frog (Xenopus laevis) from which it takes its name, xenobots are less than a millimeter (0.04 inches) wide. The tiny blobs were first unveiled in 2020 after experiments showed that they could move, work together in groups and self-heal.
Continue reading “World’s first living robots can now reproduce, scientists say” »
Circa 2017
“Enabling early detection of diseases is one of the greatest opportunities we have for developing effective treatments,” Esfandyarpour said. “Maybe $1 in the U.S. doesn’t count that much, but somewhere in the developing world, it’s a lot of money.”
Continue reading “Scientists develop ‘lab on a chip’ that costs 1 cent to make” »
Circa 2018 #artificialintelligence #doctor
Abstract: Online symptom checkers have significant potential to improve patient care, however their reliability and accuracy remain variable. We hypothesised that an artificial intelligence (AI) powered triage and diagnostic system would compare favourably with human doctors with respect to triage and diagnostic accuracy. We performed a prospective validation study of the accuracy and safety of an AI powered triage and diagnostic system. Identical cases were evaluated by both an AI system and human doctors. Differential diagnoses and triage outcomes were evaluated by an independent judge, who was blinded from knowing the source (AI system or human doctor) of the outcomes. Independently of these cases, vignettes from publicly available resources were also assessed to provide a benchmark to previous studies and the diagnostic component of the MRCGP exam. Overall we found that the Babylon AI powered Triage and Diagnostic System was able to identify the condition modelled by a clinical vignette with accuracy comparable to human doctors (in terms of precision and recall). In addition, we found that the triage advice recommended by the AI System was, on average, safer than that of human doctors, when compared to the ranges of acceptable triage provided by independent expert judges, with only a minimal reduction in appropriateness.
From: Yura Perov N [view email]
Biodiversity conservation, public health and improved livelihoods — dr gladys kalema-zikusoka, founder and CEO, conservation through public health.
Dr. Gladys Kalema-Zikusoka, is the Founder and CEO of Conservation Through Public Health (CTPH — https://ctph.org/), a 16-year old non-profit organization, based in Uganda, that promotes conservation by improving the quality of life of people and wildlife to enable them to coexist in and around protected areas in Africa, and she has become one of the leading conservationists and scientists working to save the critically endangered mountain gorillas of East Africa.
Bridging Technology And Medicine For The Modern Healthcare Ecosystem — Dr. Mona G. Flores, MD, Global Head of Medical AI, NVIDIA.
Dr. Mona Flores M.D., is the Global Head of Medical AI, at NVIDIA (https://blogs.nvidia.com/blog/author/monaflores/), the American multinational technology company, where she oversees the company’s AI initiatives in medicine and healthcare to bridge the chasm between technology and medicine.
U.S. health officials on Wednesday reported the country’s first case of the Omicron variant of the coronavirus, in a person in California.
The Covid-19 case was identified by the California and San Francisco health departments in a person who had traveled to South Africa and returned on Nov. 22, the Centers for Disease Control and Prevention said in a release. The individual, who was fully vaccinated with the Moderna shot but had not received a booster, had mild symptoms and has since recovered, federal and local officials said. The person has been isolating since testing positive on Nov. 29. All close contacts have tested negative thus far.
The discovery of Omicron in the United States is not a surprise. Upon characterizing the mutations in the variant, scientists in South Africa last week quickly raised the world’s alarms about the potential threat it posed, but it had already started to circulate silently. Some two dozen countries, from the United Kingdom to Australia to Israel, have already reported cases, many in travelers.
The new Covid variant omicron will likely “overwhelm the whole world” in the coming months, according to Singapore doctor Leong Hoe Nam.
